⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

ASTERDM - Investment Analysis: Buy Signal or Bull Trap?

← Back to List

⭐ Rating: 2.3

Last Updated Time : 18 Sept 26, 09:18 pm

Key Parameters

⭐ Investment Rating: 2.3

ROE9.45 %
ROCE10.9 %
PEG Ratio8.95
Dividend Yield0.39 %
Debt to equity0.43
PAT Qtr60.4 Cr.
PAT Prev Qtr85.3 Cr.
Qtr Profit Var-28.0 %
Show all parameters (20 more)
Stock CodeASTERDM
Market Cap65,737 Cr.
Current Price754 ₹
High / Low891 ₹
Stock P/E212
Book Value77.0 ₹
Face Value10.0 ₹
DMA 50782 ₹
DMA 200722 ₹
Chg in FII Hold-6.86 %
Chg in DII Hold-11.1 %
RSI43.7
MACD-11.3
Volume6,47,704
Avg Vol 1Wk9,15,278
Low price519 ₹
High price891 ₹
52w Index63.2 %
EPS3.34 ₹
Industry PE49.9

🏭 Industry

The healthcare sector, particularly specialized diagnostics and clinics, remains a growing industry driven by increasing healthcare expenditure and rising awareness of preventive care globally. Competition within this sector can be intense, requiring sustained investment in quality and innovation to maintain market share; however, Aster DM has established a strong presence in the Middle East.

✅ Positive

The company demonstrates consistent profitability, generating ₹60.4 Cr in the latest quarter compared to ₹85.3 Cr previously. Furthermore, the debt-to-equity ratio of 0.43 indicates a conservative capital structure, providing financial flexibility and stability for long-term investments.

⚠️ Limitation

The significantly elevated P/E ratio of 212 relative to the industry average of 49.9 suggests the stock is currently richly valued. This high valuation combined with recent downgrades raises concerns about potential overvaluation and could limit upside growth, particularly if earnings declines continue. The negative news regarding a downgrade adds uncertainty.

📉 Company Negative News

Recent news indicates a downgrade from MarketsMojo due to technical and financial concerns, alongside an ICRA rating upgrade for KIMS Healthcare – suggesting focused risk reduction at the parent level, but not necessarily reflecting ASTERDM’s core performance.

🧾 Long-Term Outlook

An ideal entry price zone would be between ₹700 – 730₹, representing a modest discount to the current price. Holding for 5-7 years is appropriate given the company’s consistent profitability and manageable debt levels. The high P/E ratio necessitates careful monitoring; if ROE and ROCE maintain their current levels and the company continues to demonstrate prudent capital management, this stock represents a reasonable long-term investment. However, should earnings decline significantly or the valuation prove unsustainable, an exit strategy would be warranted.

Choose Technical Analysis or Fundamental Analysis above to load it.

How ASTERDM Rates Across All Strategies

★ 2.3
Enter a long position at 745 ₹, targeting a stop-loss order at 720 ₹…
★ 2.3
A conservative entry point would be 748 ₹ – just below the current le…
Investment
★ 2.3
You're viewing this analysis below.
★ 2.3
Short-term entry zones would be between 745 ₹ (support level near the…
★ 2.3
We recommend a cautious entry zone around 680-710 ₹, reflecting a sli…

NIFTY 50 · Investment

NEXT 50 · Investment

MIDCAP · Investment

SMALLCAP · Investment